文献速递消化系统肿瘤

阿替利珠单抗联合或不联合考比替尼对比瑞戈非尼治疗经治转移性结直肠癌(IMblaze370):一项多中心、开放标签、3期随机对照试验

Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial.
PubMed 文献 · Lancet Oncol · 2019-04-16

IMblaze370研究在11个国家73个中心纳入363例经至少二线系统化疗后进展或不耐受的不可切除局部晚期或转移性结直肠癌患者,按2:1:1随机分配至阿替利珠单抗联合考比替尼组、阿替利珠单抗单药组或瑞戈非尼组。主要终点总生存期未达到:联合组对比瑞戈非尼的HR为1.00(95%CI 0.73-1.38;p=0.99),阿替利珠单抗对比瑞戈非尼的HR为1.19(95%CI 0.83-1.71;p=0.34)。

要点

  • 阿替利珠单抗联合考比替尼或阿替利珠单抗单药对比瑞戈非尼均未改善总生存期。
  • 联合组3-4级不良事件发生率为61%(109/179),阿替利珠单抗组为31%(28/90),瑞戈非尼组为58%(46/80)。
  • 联合组发生2例治疗相关死亡(脓毒症),瑞戈非尼组发生1例(肠穿孔)。

核心结论

  • IMblaze370未达到主要终点,阿替利珠单抗联合考比替尼或阿替利珠单抗单药对比瑞戈非尼均未改善总生存期。
  • 阿替利珠单抗联合考比替尼的安全性与其单药安全性一致。
  • 结果凸显将免疫治疗获益扩展至肿瘤基线免疫炎症水平较低患者(如微卫星稳定型转移性结直肠癌)的挑战。

研究设计与样本

  • IMblaze370为多中心、开放标签、3期随机对照试验,在11个国家的73个学术医学中心和社区肿瘤实践中进行。
  • 纳入年龄≥18岁、不可切除局部晚期或转移性结直肠癌、基线ECOG体能状态0-1、既往至少两种系统化疗方案治疗期间或之后疾病进展或不耐受的患者。
  • 采用置换区组随机化(区组大小4),通过交互式语音和网络应答系统按2:1:1分配至阿替利珠单抗联合考比替尼组、阿替利珠单抗单药组或瑞戈非尼组。
  • 分层因素为扩展RAS状态(野生型 vs 突变型)和自首次转移诊断至今的时间(<18个月 vs ≥18个月)。
  • 高微卫星不稳定患者入组上限为5%。

主要发现

  • 2016年7月27日至2017年1月19日共入组363例患者:阿替利珠单抗联合考比替尼组183例,阿替利珠单抗组90例,瑞戈非尼组90例。
  • 数据截止2018年3月9日,中位随访7.3个月(IQR 3.7-13.6)。
  • 中位总生存期:阿替利珠单抗联合考比替尼组8.87个月(95%CI 7.00-10.61),阿替利珠单抗组7.10个月(95%CI 6.05-10.05),瑞戈非尼组8.51个月(95%CI 6.41-10.71)。
  • 联合组对比瑞戈非尼的HR为1.00(95%CI 0.73-1.38;p=0.99);阿替利珠单抗对比瑞戈非尼的HR为1.19(95%CI 0.83-1.71;p=0.34)。
  • 3-4级不良事件:阿替利珠单抗联合考比替尼组109/179例(61%),阿替利珠单抗组28/90例(31%),瑞戈非尼组46/80例(58%)。

关键数值与推荐

  • 阿替利珠单抗联合考比替尼组给药方案:阿替利珠单抗840 mg静脉注射每2周一次,考比替尼60 mg口服每日一次,28天周期第1-21天。
  • 阿替利珠单抗单药组给药方案:阿替利珠单抗1200 mg静脉注射每3周一次。
  • 瑞戈非尼组给药方案:瑞戈非尼160 mg口服每日一次,28天周期第1-21天。
  • 联合组最常见全因3-4级不良事件:腹泻20/179例(11%)、贫血10/179例(6%)、血肌酸磷酸激酶升高12/179例(7%)、疲乏8/179例(4%)。
  • 严重不良事件:联合组71/179例(40%),阿替利珠单抗组15/90例(17%),瑞戈非尼组18/80例(23%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Microsatellite-stable metastatic colorectal cancer is typically unresponsive to immunotherapy. This phase 3 study was designed to assess atezolizumab plus cobimetinib in metastatic colorectal cancer. Here, we report the comparison of atezolizumab plus cobimetinib or atezolizumab monotherapy versus regorafenib in the third-line setting. METHODS: IMblaze 370 is a multicentre, open-label, phase 3, randomised, controlled trial, done at 73 academic medical centres and community oncology practices in 11 countries. Patients aged at least 18 years with unresectable locally advanced or metastatic colorectal cancer, baseline Eastern Cooperative Oncology Group performance status of 0-1, and disease progression on or intolerance to at least two previous systemic chemotherapy regimens were enrolled. We used permuted-block randomisation (block size four) to assign patients (2:1:1) via an interactive voice and web response system to atezolizumab (840 mg intravenously every 2 weeks) plus cobimetinib (60 mg orally once daily for days 1-21 of a 28-day cycle), atezolizumab monotherapy (1200 mg intravenously every 3 weeks), or regorafenib (160 mg orally once daily for days 1-21 of a 28-day cycle). Stratification factors were extended RAS status (wild-type vs mutant) and time since diagnosis of first metastasis (<18 months vs ≥18 months). Recruitment of patients with high microsatellite instability was capped at 5%. The primary endpoint was overall survival in the intention-to-treat population. Safety was assessed in the population of patients who received at least one dose of their assigned treatment. IMblaze370 is ongoing and is registered with ClinicalTrials.gov, number NCT02788279. FINDINGS: Between July 27, 2016, and Jan 19, 2017, 363 patients were enrolled (183 patients in the atezolizumab plus cobimetinib group, 90 in the atezolizumab group, and 90 in the regorafenib group). At data cutoff (March 9, 2018), median follow-up was 7·3 months (IQR 3·7-13·6). Median overall survival was 8·87 months (95% CI 7·00-10·61) with atezolizumab plus cobimetinib, 7·10 months (6·05-10·05) with atezolizumab, and 8·51 months (6·41-10·71) with regorafenib; the hazard ratio was 1·00 (95% CI 0·73-1·38; p=0·99) for the combination versus regorafenib and 1·19 (0·83-1·71; p=0·34) for atezolizumab versus regorafenib. Grade 3-4 adverse events were reported in 109 (61%) of 179 patients in the atezolizumab plus cobimetinib group, 28 (31%) of 90 in the atezolizumab group, and 46 (58%) of 80 in the regorafenib group. The most common all-cause grade 3-4 adverse events in the combination group were diarrhoea (20 [11%] of 179), anaemia (ten [6%]), increased blood creatine phosphokinase (12 [7%]), and fatigue (eight [4%]). Serious adverse events were reported in 71 (40%) of 179 patients in the combination group, 15 (17%) of 90 in the atezolizumab group, and 18 (23%) of 80 in the regorafenib group. Two treatment-related deaths occurred in the combination group (sepsis) and one in the regorafenib group (intestinal perforation). INTERPRETATION: IMblaze370 did not meet its primary endpoint of improved overall survival with atezolizumab plus cobimetinib or atezolizumab versus regorafenib. The safety of atezolizumab plus cobimetinib was consistent with those of the individual drugs. These results underscore the challenge of expanding the benefit of immunotherapy to patients whose tumours have lower baseline levels of immune inflammation, such as those with microsatellite-stable metastatic colorectal cancer. FUNDING: F Hoffmann-La Roche Ltd/Genentech Inc.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Eng C, Kim TW, Bendell J, et al. Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol. 2019. PMID: 31003911. doi:10.1016/S1470-2045(19)30027-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。